Potential Tariff Impact on Availability & Accessibility of Medications for Telehealth Patients
March 4th 2025In this Pharmaceutical Executive Video Interview, Peter Ax, Founder & CEO of UpScriptHealth, explores how tariffs could affect the availability and accessibility of specific medications, particularly for patients relying on direct-to-patient telehealth.
Pharma’s Turn to Peer-to-Patient Platforms and Trusted Patient Communities
March 4th 2025In this Pharmaceutical Executive video interview, Jen Butler, Chief Commercial Officer for Pleio, discusses why pharma increasingly turning to peer-to-patient platforms to educate patients, as well as relationships with trusted patient communities and pharmacies.
How Pharmaceutical Companies Can Mitigate a Potential Drop in Demand Due to Tariffs
March 3rd 2025In this part of his Pharmaceutical Executive Video Interview, Peter Ax, Founder & CEO of UpScriptHealth, identifies strategies that pharmaceutical companies and digital health platforms can employ to navigate a potential drop in demand due to tariff-induced increased costs.
How Tariffs Will Drive Up Pharmaceutical Costs & Which Drug Categories Will Be Most Affected
February 28th 2025In this Pharmaceutical Executive Video Interview, Peter Ax, Founder & CEO of UpScriptHealth, addresses how tariffs will affect pharmaceutical costs and which drug categories will be most affected.
Where Patients are Turning for Trustworthy Health Information
February 27th 2025In this Pharmaceutical Executive video interview, Jen Butler, Chief Commercial Officer for Pleio, talks about where patients are turning for trustworthy health information and some strategies that can be used to verify information.
Strong Safety and Tolerability in Phase I Trials for IMU-856 Supports Broad GI Applications
February 26th 2025Daniel Vitt, CEO, Immunic Therapeutics, discusses how the safety and tolerabilities results from Phase I trials for IMU-856 influences further studies for gastrointestinal diseases moving forward.